POLR2J4 has been reported as a composition of signature to predict the survival of cirrhotic hepatocellular carcinoma and recurrence-free hepatocellular carcinoma (Gu et al., 2019; Ma and Deng, 2019). Here, POLR2J4 is linked to hepatocellular carcinoma.